CeaproTSXV: CZO

Ceapro rebrands patented diabetes technology as CeaProve(TM)

· Issued by Ceapro via CNW
EDMONTON, April 12 /CNW/ - Ceapro Inc. (TSX-V: CZO) today announced the
rebranding of its lead diabetes diagnostic technology as CeaProve(TM).
"As a result of the 2004 pre-market activities, it became clear that our
diabetes technology extended beyond accurate screening with results indicating
applications in both diabetes AND pre-diabetes, for screening, diagnosis, and
monitoring," said Mr. Oleh Hnatiuk, Acting Managing Director of Ceapro
Technology Inc. "With this expansion of applications, we have branded our
diabetes technology as CeaProve(TM). CeaProve(TM) is clearly a new product
with use in new markets of pre-diabetes detection and diabetes prevention,"
Mr. Hnatiuk continued. "During 2004, we discovered new applications in the
area of diabetes monitoring and drug dosage determination. We are more
convinced than ever that CeaProve(TM) represents breakthrough technology that
will occupy a critical place in global health and wellness strategies."
This week, Ceapro will unveil CeaProve(TM) to the world at The First
International Congress on Pre-diabetes and the Metabolic Syndrome, in Berlin,
Germany, from April 13-16, 2005. The congress is dedicated to communicating
the advances in the field and will serve as a platform in which screening and
intervention will be presented and evaluated. Further information can be found
on the congress' website at: www.kenes.com/pre-diabetes.

2004 Financial Results and Annual and Special Meeting
Ceapro will release its 2004 financial results on or before April 29,
2005. The Company's annual report, containing Management's Discussion and
Analysis and Audited Financial Statements, will be mailed to shareholders on
or about May 2, 2005. Ceapro's annual and special meeting of shareholders will
be held on Wednesday, June 1, 2005, at Lister Centre, University of Alberta,
at 3:00 p.m. MDT

About CeaProve(TM)
CeaProve(TM) is a simple, cost effective, and rapid point-of-care tool to
detect the elevated blood glucose levels indicative of pre-diabetic and
diabetic conditions. CeaProve(TM) consists of calibrated wafers made from a
proprietary formulation of proteins, fats, and complex carbohydrates that are
consumed with a glass of water after an overnight fast. A quick analysis of
the blood, using one of many standard glucose meters presently on the market,
provides an on-the-spot indication of elevated blood glucose levels. Ceapro is
pursuing several strategies to position CeaProve(TM) for sale and distribution
to the public. These include selling the product over the counter at Canadian
pharmacies and a global partnership strategy for international markets.

About Ceapro Inc.
Ceapro Inc., an innovation-driven biotechnology company, develops and
commercializes organic products for medical, cosmetic, and animal health
industries using proprietary technology and natural, renewable resources.
Based in Edmonton, Alberta, Ceapro is one of Alberta Venture's Fastest Growing
Companies for 2004 and 2005 and is one of Profit Magazine's Next 100
Companies. Ceapro is also the recipient of the ASTech Award for Outstanding
Commercial Achievement for companies with annual sales of less than
$25 million. Ceapro's shares trade on the TSX Venture Exchange under the
symbol CZO. To learn more about Ceapro, log on to our website at
www.ceapro.com. Shares Outstanding: 36,355,950, Recent Close: $0.275.

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or the accuracy of this news release.

This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements. Although the Company believes that the forward-
looking statements contained herein are reasonable, it can give no assurance
that the Company's expectations are correct. All forward-looking statements
are expressly qualified in their entirety by this cautionary statement.
%SEDAR: 00010110E

Ceapro on 6ix

Later from Ceapro

All Ceapro news releases